239 related articles for article (PubMed ID: 31054432)
21. Synthesis, characterization, biological evaluation and molecular docking of a new quinazolinone-based derivative as a potent dual inhibitor for VEGFR-2 and EGFR tyrosine kinases.
Riadi Y; Alamri MA; Geesi MH; Anouar EH; Ouerghi O; Alabbas AB; Alossaimi MA; Altharawi A; Dehbi O; Alqahtani SM
J Biomol Struct Dyn; 2022 Sep; 40(15):6810-6816. PubMed ID: 33682611
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis and biological evaluation of novel 2-(4-(1H-indazol-6-yl)-1H-pyrazol-1-yl)acetamide derivatives as potent VEGFR-2 inhibitors.
Wang XR; Wang S; Li WB; Xu KY; Qiao XP; Jing XL; Wang ZX; Yang CJ; Chen SW
Eur J Med Chem; 2021 Mar; 213():113192. PubMed ID: 33493829
[TBL] [Abstract][Full Text] [Related]
23. Synthesis, cytotoxic evaluation, and molecular docking studies of novel quinazoline derivatives with benzenesulfonamide and anilide tails: Dual inhibitors of EGFR/HER2.
Alkahtani HM; Abdalla AN; Obaidullah AJ; Alanazi MM; Almehizia AA; Alanazi MG; Ahmed AY; Alwassil OI; Darwish HW; Abdel-Aziz AA; El-Azab AS
Bioorg Chem; 2020 Jan; 95():103461. PubMed ID: 31838290
[TBL] [Abstract][Full Text] [Related]
24. Novel 4-(piperazin-1-yl)quinolin-2(1H)-one bearing thiazoles with antiproliferative activity through VEGFR-2-TK inhibition.
Hassan A; Badr M; Hassan HA; Abdelhamid D; Abuo-Rahma GEA
Bioorg Med Chem; 2021 Jun; 40():116168. PubMed ID: 33962153
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis and docking study of novel picolinamide derivatives as anticancer agents and VEGFR-2 inhibitors.
Zeidan MA; Mostafa AS; Gomaa RM; Abou-Zeid LA; El-Mesery M; El-Sayed MA; Selim KB
Eur J Med Chem; 2019 Apr; 168():315-329. PubMed ID: 30826508
[TBL] [Abstract][Full Text] [Related]
26. Design and synthesis of new 1,6-dihydropyrimidin-2-thio derivatives targeting VEGFR-2: Molecular docking and antiproliferative evaluation.
Marzouk AA; Abdel-Aziz SA; Abdelrahman KS; Wanas AS; Gouda AM; Youssif BGM; Abdel-Aziz M
Bioorg Chem; 2020 Sep; 102():104090. PubMed ID: 32683176
[TBL] [Abstract][Full Text] [Related]
27. Synthesis, anticancer and apoptosis-inducing activities of quinazoline-isatin conjugates: epidermal growth factor receptor-tyrosine kinase assay and molecular docking studies.
El-Azab AS; Al-Dhfyan A; Abdel-Aziz AA; Abou-Zeid LA; Alkahtani HM; Al-Obaid AM; Al-Gendy MA
J Enzyme Inhib Med Chem; 2017 Dec; 32(1):935-944. PubMed ID: 28718672
[TBL] [Abstract][Full Text] [Related]
28. Discovery of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors: Design, synthesis, and anti-proliferative evaluation.
Eissa IH; El-Helby AA; Mahdy HA; Khalifa MM; Elnagar HA; Mehany ABM; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; El-Adl K
Bioorg Chem; 2020 Dec; 105():104380. PubMed ID: 33128967
[TBL] [Abstract][Full Text] [Related]
29. Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors.
Wei H; Duan Y; Gou W; Cui J; Ning H; Li D; Qin Y; Liu Q; Li Y
Eur J Med Chem; 2019 Nov; 181():111552. PubMed ID: 31387063
[TBL] [Abstract][Full Text] [Related]
30. Design and Synthesis of Novel Coumarin Conjugated Acetamides as Promising Anticancer Agents: An In Silico and In Vitro Approach.
Mamatha SV; Belagali SL; Bhat M; Kumbar VM
Anticancer Agents Med Chem; 2021; 21(11):1431-1440. PubMed ID: 32664844
[TBL] [Abstract][Full Text] [Related]
31. Identification of novel ureido benzothiophenes as dual VEGFR-2/EGFR anticancer agents.
Eldehna WM; Al-Ansary GH; Al-Warhi T; Jaballah MY; Elaasser M; Rashed M
Bioorg Chem; 2024 Feb; 143():107037. PubMed ID: 38134521
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors.
Sever B; Altıntop MD; Radwan MO; Özdemir A; Otsuka M; Fujita M; Ciftci HI
Eur J Med Chem; 2019 Nov; 182():111648. PubMed ID: 31493743
[TBL] [Abstract][Full Text] [Related]
33. Design, Synthesis, Molecular Docking, and Anticancer Activity of Phthalazine Derivatives as VEGFR-2 Inhibitors.
El-Helby AA; Ayyad RRA; Sakr H; El-Adl K; Ali MM; Khedr F
Arch Pharm (Weinheim); 2017 Dec; 350(12):. PubMed ID: 29131379
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis, molecular docking, and anticancer activity of benzoxazole derivatives as VEGFR-2 inhibitors.
El-Helby AA; Sakr H; Eissa IH; Abulkhair H; Al-Karmalawy AA; El-Adl K
Arch Pharm (Weinheim); 2019 Oct; 352(10):e1900113. PubMed ID: 31448458
[TBL] [Abstract][Full Text] [Related]
35. Discovery of N-(2-phenyl-1H-benzo[d]imidazol-5-yl)quinolin-4-amine derivatives as novel VEGFR-2 kinase inhibitors.
Shi L; Wu TT; Wang Z; Xue JY; Xu YG
Eur J Med Chem; 2014 Sep; 84():698-707. PubMed ID: 25064347
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis and in vitro evaluation of 6-amide-2-aryl benzoxazole/benzimidazole derivatives against tumor cells by inhibiting VEGFR-2 kinase.
Yuan X; Yang Q; Liu T; Li K; Liu Y; Zhu C; Zhang Z; Li L; Zhang C; Xie M; Lin J; Zhang J; Jin Y
Eur J Med Chem; 2019 Oct; 179():147-165. PubMed ID: 31252306
[TBL] [Abstract][Full Text] [Related]
37. Design, synthesis, in silico and antiproliferative evaluation of novel pyrazole derivatives as VEGFR-2 inhibitors.
Ravula P; Vamaraju HB; Paturi M; Sharath Chandra JNGN
Arch Pharm (Weinheim); 2018 Jan; 351(1):. PubMed ID: 29205467
[TBL] [Abstract][Full Text] [Related]
38. Design, synthesis and in silico insights of new 7,8-disubstituted-1,3-dimethyl-1H-purine-2,6(3H,7H)-dione derivatives with potent anticancer and multi-kinase inhibitory activities.
Mohamed AR; El Kerdawy AM; George RF; Georgey HH; Abdel Gawad NM
Bioorg Chem; 2021 Feb; 107():104569. PubMed ID: 33387732
[TBL] [Abstract][Full Text] [Related]
39. Discovery of novel rigid analogs of 2-naphthol with potent anticancer activity through multi-target topoisomerase I & II and tyrosine kinase receptor EGFR & VEGFR-2 inhibition mechanism.
El-Mawgoud HKA; Fouda AM; El-Nassag MAA; Elhenawy AA; Alshahrani MY; El-Agrody AM
Chem Biol Interact; 2022 Mar; 355():109838. PubMed ID: 35123995
[TBL] [Abstract][Full Text] [Related]
40. Design and synthesis of some new 6-bromo-2-(pyridin-3-yl)-4-substituted quinazolines as multi tyrosine kinase inhibitors.
Farouk AKBAW; Abdelrasheed Allam H; Rashwan E; George RF; Abbas SE
Bioorg Chem; 2022 Nov; 128():106099. PubMed ID: 35994884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
